Toward this question, we performed a triple immunofluorescence assay on KS clinic samples for a mesenchymal marker (Nestin, PDGFRA, or α-SAM), an endothelial marker (PDPN, CD31, or VEGFR2), and a KSHV marker (LANA). This evidence concerns the gene KDR and Kaposi's sarcoma.